ArticleAmerican journal of cancer research2025
Resistance patterns of non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred therapy for patients with EGFR mutant non-small cell lung cancer (NSCLC); however, the therapy faces resistance challenges. We aimed to clarify the resistance patterns of EGFR-TKIs in patients with EGFR mutant NSCLC. In this retrospective study, we analyzed 104 patients with advanced EGFR mutant NSCLC who experienced treatment failure of third-generation EGFR-TKIs. Resistance models were classified as 1) original site failure (OF), distant site failure (DF), and combined failure (ODF) based on the failure site or 2) oligo-progression (OP) and non-oligoprogression based on the disease progression (PD) pattern. Among the patients, 58.7% (n = 61 of 104) developed OF, while 25 (24.0%) and 18 (17.3%) developed DF and ODF, respectively. A high OP rate (76.9%, n = 80) was observed, with primary progression accounting for 30.8%. OF was related to sex (odds ratio = 3.961, 95% confidence interval: 1.629-9.631, P = 0.002). Over 50% of patients with third-generation EGFR-TKI treatment failure developed OF. Sex, central nervous system metastases, and disease stage influenced the resistance patterns of the EGFR-TKI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.